DelveInsight’s, “Advanced Cervical Cancer Pipeline Insight, 2023,” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Advanced Cervical Cancer pipeline landscape. It covers the pipeline drug profiles, including Advanced Cervical Cancer clinical trials and nonclinical stage products. It also covers the Advanced Cervical Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Advanced Cervical Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Advanced Cervical Cancer clinical trials studies, Advanced Cervical Cancer NDA approvals (if any), and product development activities comprising the technology, Advanced Cervical Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key Takeaways from the Advanced Cervical Cancer Pipeline Report
To explore more information on the latest breakthroughs in the Advanced Cervical Cancer Pipeline treatment landscape of the report, click here @ Advanced Cervical Cancer Pipeline Outlook
Recent Developmental Activities in the Advanced Cervical Cancer Treatment Landscape
Advanced Cervical Cancer Overview
Advanced cervical cancer means the cancer has spread from the cervix to another area of the body such as the lungs. Sometimes cancer is advanced when it is first diagnosed. Unfortunately advanced cancer can’t usually be cured. But treatment might control it, help symptoms, and improve your quality of life for a while. The most common places for cervical cancer to spread is to the lymph nodes, liver, lungs and bones. Treatment for advanced cervical cancer depends on the size of the cancer and where it is in the body. Chemotherapy can be used to treat advanced cervical cancer. Some women may have an operation called pelvic exenteration for cervical cancer that has come back within the pelvis.
Request a sample and discover the recent advances in Advanced Cervical Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Advanced Cervical Cancer Treatment Landscape
Advanced Cervical Cancer Emerging Drugs Profile
Imfinzi (durvalumab): AstraZeneca
Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses. Imfinzi is the only approved immunotherapy in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiotherapy, and is the global standard of care in this setting based on the PACIFIC Phase III trial. Imfinzi is also approved in the US, EU, Japan, China and many other countries around the world for the treatment of extensive-stage small cell lung cancer based on the CASPIAN Phase III trial. As part of a broad development programme, Imfinzi is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with small cell lung cancer, NSCLC, bladder cancer, several gastrointestinal cancers, ovarian cancer, endometrial cancer and other solid tumours. Currently, it is in Phase III stage of clinical trial evaluation to treat Locally Advanced Cervical Cancer.
Dostarlimab: GlaxoSmithKline
Dostarlimab is a humanised PD-1 monoclonal antibody that binds with high affinity to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2. Currently, it is in Phase II stage of clinical trial evaluation to treat Locally Advanced Cervical Cancer.
Andes 1537: Andes Biotechnologies
Andes-1537, a proprietary antisense oligonucleotide designed by Andes Biotechnology, is the Company’s most advanced investigational drug candidate and the first to enter a human clinical study. It targets a novel non-coding mitochondrial RNA (ncmtRNA) and has demonstrated antineoplastic activity in preclinical studies. Upon administration, Andes-1537 binds to a specific ncmtRNA, inducing cell cycle arrest and apoptosis of cancer cells. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Cervical Cancer.
Advanced Cervical Cancer Pipeline Therapeutics Assessment
There are approx. 70+ key companies which are developing the therapies for Advanced Cervical Cancer. The companies which have their Advanced Cervical Cancer drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.
For further information, refer to the detailed Advanced Cervical Cancer Unmet Needs, Advanced Cervical Cancer Market Drivers, and Market Barriers, click here for Advanced Cervical Cancer Ongoing Clinical Trial Analysis
Scope of the Advanced Cervical Cancer Pipeline Report
Dive deep into rich insights for drugs for Advanced Cervical Cancer Market Drivers and Advanced Cervical Cancer Market Barriers, click here @ Advanced Cervical Cancer Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Advanced Cervical Cancer Mergers and acquisitions, Advanced Cervical Cancer licensing activities @ Advanced Cervical Cancer Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services